{
    "clinical_study": {
        "@rank": "139817", 
        "arm_group": [
            {
                "arm_group_label": "Anecortave and Sham PDT", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "PDT and Sham Anecortave Acetate", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that Anecortave Acetate is as effective after\n      twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible\n      for initial PDT treatment for wet age-related macular degeneration."
        }, 
        "brief_title": "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD", 
        "completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "condition": "Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV\n        due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to\n        20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases\n        will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "530", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 9, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00041483", 
            "org_study_id": "C-01-99"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Anecortave and Sham PDT", 
                    "PDT and Sham Anecortave Acetate"
                ], 
                "intervention_name": "Anecortave Acetate 15 mg sterile suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Anecortave and Sham PDT", 
                    "PDT and Sham Anecortave Acetate"
                ], 
                "intervention_name": "Photodynamic Therapy (PDT)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Verteporfin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AMD", 
            "age-related macular degeneration", 
            "Anecortave", 
            "Acetate", 
            "Wet form of age-related macular degeneration"
        ], 
        "lastchanged_date": "November 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ft. Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients Maintaining Vision", 
            "safety_issue": "No", 
            "time_frame": "Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2008"
    }, 
    "geocoordinates": {
        "Contact Alcon Call Center for Trial Locations": "32.725 -97.321"
    }
}